Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)

Basit Öğe Kaydı
dc.contributor.authorArtac, Mehmet
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorKiyici, Aysel
dc.contributor.authorEren, Orhan Onder
dc.contributor.authorBoruban, Melih Cem
dc.contributor.authorOzdogan, Mustafa
dc.date.accessioned2020-03-26T18:43:19Z
dc.date.available2020-03-26T18:43:19Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description46th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2010 -- Chicago, ILen_US
dc.description.abstractOur objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Median age was 51 years (range 28-75). Median leptin level was 19400 pg/ml (1970-91900) and estradiol level 29.6 pg/ml (4.0-181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was a parts per thousand yen19400 pg/ml (HR = 0.38; 95% CI: 0.16-0.91). This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1007/s12282-011-0322-1en_US
dc.identifier.endpage180en_US
dc.identifier.issn1340-6868en_US
dc.identifier.issn1880-4233en_US
dc.identifier.issue2en_US
dc.identifier.pmid22203581en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage174en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s12282-011-0322-1
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29807
dc.identifier.volume20en_US
dc.identifier.wosWOS:000317011900010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGER JAPAN KKen_US
dc.relation.ispartofBREAST CANCERen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectMetastatic breast canceren_US
dc.subjectLeptinen_US
dc.subjectWaist-to-hip ratioen_US
dc.subjectWeighten_US
dc.subjectAromatase inhibitorsen_US
dc.subjectHormonal therapyen_US
dc.titleSerum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu